-
Sector Analysis
NewContrast Agents Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033
Contrast Agents Market Report Overview The contrast agents market size was $3.41 billion in 2023. Factors such as the rising prevalence of chronic diseases and the increased demand for cost-effective and quality healthcare will drive the market growth at a CAGR of more than 2% from 2023 to 2033. Contrast agents are used in radiology to get clearer visualizations of various medical conditions and pathologies. These agents are used with computed tomography (CT), magnetic resonance imaging (MRI), and ultrasounds, among...
-
Sector Analysis
NewNuclear Imaging Agents Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033
Nuclear Imaging Agents Market Report Overview The nuclear imaging agents market size was $998 million in 2023. Factors such as technical advancements and applied research will drive the market growth at a CAGR of more than 2% from 2023 to 2033. Nuclear imaging is a non-invasive medical technique that uses radioactive tracers (generally F-18 Fluorodeoxyglucose) to assess and diagnose bodily functions and diseases. The diseases include cancers, cardiac diseases, gastrointestinal, endocrine, and neurological diseases. Nuclear Imaging Agents Market Outlook 2023-2033...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AGENT-797 in Esophageal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AGENT-797 in Esophageal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AGENT-797 in Esophageal Cancer Drug Details: AGENT-797 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AGENT-797 in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AGENT-797 in Pancreatic Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AGENT-797 in Pancreatic Cancer Drug Details: AGENT-797 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AGENT-797 in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AGENT-797 in Gastric Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AGENT-797 in Gastric Cancer Drug Details: AGENT-797 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AGENT-797 in Hepatocellular Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AGENT-797 in Hepatocellular Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AGENT-797 in Hepatocellular Carcinoma Drug Details: AGENT-797 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AGENT-797 in Rectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AGENT-797 in Rectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AGENT-797 in Rectal Cancer Drug Details: AGENT-797 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AGENT-797 in Testicular Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AGENT-797 in Testicular Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AGENT-797 in Testicular Cancer Drug Details: AGENT-797 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AGENT-797 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AGENT-797 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AGENT-797 in Solid Tumor Drug Details: AGENT-797 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AGENT-797 in Prostate Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AGENT-797 in Prostate Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AGENT-797 in Prostate Cancer Drug Details: AGENT-797 is under development for...